Acklin, Scarlett
Zhang, Manchao
Du, Wuying
Zhao, Xin
Plotkin, Matthew
Chang, Jianhui
Campisi, Judith
Zhou, Daohong
Xia, Fen
Funding for this research was provided by:
National Institutes of Health (R01 CA188500)
Article History
Received: 29 May 2020
Accepted: 23 July 2020
First Online: 25 August 2020
Competing interests
: J.C. (J Chang), D.Z. and F.X. are inventors of a pending patent application for use of ABT263 and Bcl-xl PROTACs as senolytic agents for the treatment of age-related diseases and chemotherapy-induced peripheral neuropathy. J.C. (J Campisi) and D.Z. are co-founders and stockholders of Unity Biotechnology that develops senolytics to treat age-related diseases. S.A., M.Z., W.D., X.Z., and M.P. declare no competing interests.